EA029847B1 - Комбинированная фармацевтическая композиция и способ лечения сахарного диабета и связанных с ним метаболических расстройств - Google Patents

Комбинированная фармацевтическая композиция и способ лечения сахарного диабета и связанных с ним метаболических расстройств Download PDF

Info

Publication number
EA029847B1
EA029847B1 EA201300124A EA201300124A EA029847B1 EA 029847 B1 EA029847 B1 EA 029847B1 EA 201300124 A EA201300124 A EA 201300124A EA 201300124 A EA201300124 A EA 201300124A EA 029847 B1 EA029847 B1 EA 029847B1
Authority
EA
Eurasian Patent Office
Prior art keywords
bei
antibody
seeg
agde
pro
Prior art date
Application number
EA201300124A
Other languages
English (en)
Russian (ru)
Other versions
EA201300124A1 (ru
Inventor
Олег Ильич ЭПШТЕЙН
Original Assignee
Олег Ильич ЭПШТЕЙН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA029847(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Олег Ильич ЭПШТЕЙН filed Critical Олег Ильич ЭПШТЕЙН
Publication of EA201300124A1 publication Critical patent/EA201300124A1/ru
Publication of EA029847B1 publication Critical patent/EA029847B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201300124A 2010-07-21 2011-07-15 Комбинированная фармацевтическая композиция и способ лечения сахарного диабета и связанных с ним метаболических расстройств EA029847B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (2)

Publication Number Publication Date
EA201300124A1 EA201300124A1 (ru) 2013-12-30
EA029847B1 true EA029847B1 (ru) 2018-05-31

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300124A EA029847B1 (ru) 2010-07-21 2011-07-15 Комбинированная фармацевтическая композиция и способ лечения сахарного диабета и связанных с ним метаболических расстройств

Country Status (30)

Country Link
US (1) US8617555B2 (cg-RX-API-DMAC7.html)
EP (2) EP2595658A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013533268A (cg-RX-API-DMAC7.html)
KR (2) KR20180127515A (cg-RX-API-DMAC7.html)
CN (1) CN103118707A (cg-RX-API-DMAC7.html)
AR (1) AR082312A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011281240B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013001299A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805961A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000200A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2013124A3 (cg-RX-API-DMAC7.html)
DE (1) DE112011102396T5 (cg-RX-API-DMAC7.html)
DK (1) DK201370089A (cg-RX-API-DMAC7.html)
EA (1) EA029847B1 (cg-RX-API-DMAC7.html)
EE (1) EE05761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2445846R1 (cg-RX-API-DMAC7.html)
FI (1) FI20135152L (cg-RX-API-DMAC7.html)
FR (1) FR2962913A1 (cg-RX-API-DMAC7.html)
GB (2) GB2552405B (cg-RX-API-DMAC7.html)
IT (1) ITTO20110627A1 (cg-RX-API-DMAC7.html)
LT (1) LT5980B (cg-RX-API-DMAC7.html)
MX (1) MX2013000804A (cg-RX-API-DMAC7.html)
MY (1) MY160979A (cg-RX-API-DMAC7.html)
NO (1) NO20130265A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ606964A (cg-RX-API-DMAC7.html)
PE (1) PE20130815A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500140A1 (cg-RX-API-DMAC7.html)
SE (1) SE1350212A1 (cg-RX-API-DMAC7.html)
SG (1) SG187578A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012010966A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. ERNST: "A systematic review of systematic reviews of homeopathy", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 54, no. 6, 1 December 2002 (2002-12-01), pages 577 - 582, XP055017706, ISSN: 03065251, DOI: 10.1046/j.1365-2125.2002.01699.x *
SHANG, A. ; HUWILER-MUNTENER, K. ; NARTEY, L. ; JUNI, P. ; DORIG, S. ; STERNE, J.A. ; PEWSNER, D. ; EGGER, M.: "Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy", THE LANCET (LETTERS TO THE EDITOR), THE LANCET PUBLISHING GROUP, GB, vol. 366, no. 9487, 27 August 2005 (2005-08-27), GB, pages 726 - 732, XP025277623, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(05)67177-2 *

Also Published As

Publication number Publication date
KR20180127515A (ko) 2018-11-28
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
SG187578A1 (en) 2013-03-28
WO2012010966A2 (en) 2012-01-26
CZ2013124A3 (cs) 2013-06-12
PH12013500140A1 (en) 2013-03-11
US20130064824A1 (en) 2013-03-14
KR20130103486A (ko) 2013-09-23
GB2496799A (en) 2013-05-22
MX2013000804A (es) 2013-10-28
JP2013533268A (ja) 2013-08-22
ITTO20110627A1 (it) 2012-01-22
AR082312A1 (es) 2012-11-28
DE112011102396T5 (de) 2013-05-02
GB201707872D0 (en) 2017-06-28
NO20130265A1 (no) 2013-04-18
FR2962913A1 (fr) 2012-01-27
FI20135152A7 (fi) 2013-02-21
DK201370089A (en) 2013-02-19
CL2013000200A1 (es) 2015-01-23
EE05761B1 (et) 2016-03-15
LT2013018A (lt) 2013-10-25
AU2011281240A1 (en) 2013-03-07
US8617555B2 (en) 2013-12-31
GB2552405A (en) 2018-01-24
JP2016222684A (ja) 2016-12-28
ES2445846R1 (es) 2015-01-02
CA2805961A1 (en) 2012-01-26
GB2552405B (en) 2018-05-30
SE1350212A1 (sv) 2013-04-22
GB201302924D0 (en) 2013-04-03
ES2445846A2 (es) 2014-03-05
AU2011281240B2 (en) 2016-07-07
EP3693018A1 (en) 2020-08-12
CN103118707A (zh) 2013-05-22
PE20130815A1 (es) 2013-07-18
BR112013001299A2 (pt) 2017-11-21
WO2012010966A3 (en) 2012-03-29
NZ606964A (en) 2015-08-28
EE201300007A (et) 2013-08-15
EP2595658A2 (en) 2013-05-29
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21
MY160979A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
EA029847B1 (ru) Комбинированная фармацевтическая композиция и способ лечения сахарного диабета и связанных с ним метаболических расстройств
JP7761964B2 (ja) 心不全の治療用組成物
CA1341060C (en) Use of amylin agonists in the treatment of diabetes mellitus
EA030513B1 (ru) Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний
EA026712B1 (ru) Применение ингибитора sglt2
EA029998B1 (ru) Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
EA029860B1 (ru) Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы
EA029199B1 (ru) Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
KR20190067219A (ko) 통증 예방, 경감 또는 치료에서의 신경 흥분성 상해 관련 폴리펩타이드의 용도
KR20140009110A (ko) 심혈관계와 연관된 질환 또는 장애를 치료하기 위한 복합 제약학적 조성물과 방법
KR20150035714A (ko) C-펩타이드를 포함하는 당뇨성 혈관신생 장애의 예방 또는 치료용 조성물
RU2509572C2 (ru) Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
Aloe et al. Altered expression of nerve growth factor and its receptors in the kidneys of diabetic rats
RU2531048C2 (ru) Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2565401C2 (ru) Способ лечения сахарного диабета и комбинированное лекарственное средство
Wolfe et al. Gastric secretions
YOKOYAMA et al. Transient extreme insulin resistance in shock during diabetic ketoacidosis
WO2017062363A1 (en) Methods of use of betatrophin
Yang Involvement of adenosine signalling in the release of gastric and pancreatic peptides
Patel Evaluation of alcoholic exract of callicarpa macrophylla flower for its antidiabetic activity
Gahhos Septic shock and endorphins

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ KG RU